摘要
目的基于医院信息系统,研究乳腺癌芳香化酶抑制剂相关骨质疏松的处方用药规律。方法收集2019年1月至2021年10月首都医科大学附属北京中医医院信息系统中乳腺癌芳香化酶抑制剂相关骨质疏松患者诊疗信息,分析中药总体使用情况,对中药进行关联规则分析和聚类分析。结果共纳入184例乳腺癌芳香化酶抑制剂相关骨质疏松患者,最常见的中医证型为正虚毒结证、肝郁脾虚证、痰瘀互结证等。所有处方共涉及中药298味,中药四气以温性、平性药物为主;五味以甘、苦、辛味药物多见。药物归经以肝经为主。使用频率最高的药物类别为活血化瘀药。关联规则分析显示,置信度和支持度最高的药物组合分别是柴胡-郁金,白术-白花蛇舌草-茯苓,通过聚类分析将药物聚为4类。结论乳腺癌芳香化酶抑制剂相关骨质疏松的中医药治疗以调肝理气、化瘀通络止痛为主要治法,辅以益气解毒。
Objective To study the prescription medication rules of breast cancer aromatase inhibitor-related osteoporosis based on hospital information system.Methods The diagnosis and treatment information of breast cancer patients with aromatase inhibitor-related osteoporosis was collected from the information system of Beijing Traditional Chinese Medicine Hospital,Capital Medical University from January 2019 to October 2021.The overall use of traditional Chinese medicine was analyzed,and association rule analysis and cluster analysis were performed for traditional Chinese medicine.Results A total of 184 breast cancer patients with aromatase inhibitor-related osteoporosis were included.The most common traditional Chinese medicine syndroms were syndrome of healthy qi deficiency and toxin accumulation,syndrome of stagnation of liver qi and spleen deficiency,syndrome of intermin-gled phlegm and blood stasis,etc.All the prescriptions involved 298 kinds of traditional Chinese medicine,and the four nature of traditional Chinese medicine were mainly warm and calm drugs.Five flavours to sweet,bitter,bitter drugs more common.The main channel tropism of drugs was liver channel.The most frequently used drug category is the drugs for promoting blood circulation for removing blood stasis.Association rule analysis showed that the drug combinations with the highest confidence and support were Bupleuri Radix-Curcumae Radix,Atractylodis Macrocephalae Rhizoma-Herba Hedyotis-Radix,respectively.The drugs were grouped into four groups by cluster analysis.Conclusion The traditional Chinese medicine treatment of breast cancer aromatase inhibitor-related osteoporosis is to regulate liver and regulate qi,remove stasis,remove obstruction in collaterals,and relieve pain as the main treatment,supplemented by yiqi and detoxification.
作者
孟慧
于明薇
王笑民
陈宇晗
张佳慧
MENG Hui;YU Mingwei;WANG Xiaomin;CHEN Yuhan;ZHANG Jiahui(Department of Oncology,Beijing Traditional Chinese Medicine Hospital,Capital Medical University,Beijing 100010,China)
出处
《中国医药导报》
CAS
2022年第32期5-9,共5页
China Medical Herald
基金
北京市自然科学基金面上项目(7202065)
北京市科技计划项目(Z191100008319006)
国家重大新药创制专项(民口)项目(2019ZX09734-001)。
关键词
乳腺癌
骨质疏松
芳香化酶抑制剂
用药规律
活血化瘀
Breast cancer
Osteoporosis
Aromatase inhibitor
Medication rule
Promoting blood circulation for removing blood stasis
